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Summary 
Since the 1960s, platelet transfusion therapy has played a vital role in the management of he-
matologic and oncologic patients with quite frequent disorder: thrombocytopenia. More than 2.9 
million platelet components are transfused each year in Europe and 57,000 in Croatia. Indeed, 
platelet transfusion has long been the subject of many debates and controversies, including the 
advantage of giving prophylactic compared to therapeutic transfusion, the trigger and/or thres-
hold for platelet transfusion, the platelet collection method, and the optimal platelet dose to be 
transfused. Taking into account a short shelf life of PLTs compared to other blood components (5 
to 7 days) and a growing demand for their use, each transfusion center must decide on its own 
priorities for providing a sufficient quantity of safe and effective PLT units. 
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INTRODUCTION 
Since the 1960s, platelet transfusion therapy has played a vital role in the manage-
ment of hematologic and oncologic patients with thrombocytopenia [1]. Although pla-
telets are essential in the maintenance of normal hemostatic activity, for patients with 
thrombocytopenia (low platelet counts) or impaired platelet function, platelet transfusi-
on can be of significant value in preventing and treating hemorrhage [1,2]. Nowadays, 
many modern therapies depend on platelet transfusion support. There is an increasing 
demand for platelet transfusions due to intensive chemotherapy and blood stem cell or 
bone marrow transplantation, but also as support in numerous medical treatments in ge-
neral, such as major surgery, trauma resuscitation, and various diagnostic procedures in 
thrombocytopenic patients. More than 2.9 million platelets are transfused in Europe each 
year and 57,000 in Croatia [3]. However, the supply of platelets is limited worldwide and 
platelet transfusion is considered a financially burdensome and challenging procedure.
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In the majority of cases (more than 70%), platelet transfusions are used prophylacti-
cally, to prevent spontaneous bleeding by maintaining the platelet count above a prede-
termined transfusion trigger. In a bleeding patient with thrombocytopenia, platelets are 
transfused therapeutically, in order to achieve hemostasis [2,4-6]. There are still debates 
and controversy regarding the trigger for platelet transfusion, the optimal platelet dose 
to be transfused and the advantage of giving prophylactic compared to therapeutic tran-
sfusion. The decision to administer platelet transfusions should incorporate individual 
clinical characteristics of the patient and not simply be a reaction to the platelet count. 
Manufacture of platelet units
Platelets (PLTs) for transfusion can be collected by apheresis technology (Figure 
1.) or prepared from whole blood. In the latter case, whether PLT unit is prepared 
from the buffy coat or from platelet-rich plasma, four to six donor units are pooled 
together to produce an adult dose of PLTs. The number of PLTs per random donor 
pool varies according to the PLT count of each single donor; a yield of 3-4 x 1011 is 
preferred. Advantages of pooled platelets, when compared to apheresis, are lower 
cost and ease of collection and processing. The major disadvantage is recipient ex-
posure to multiple donors in a single transfusion [7].
A typical apheresis platelet unit (single donor platelets) provides the equivalent 
of six or more units of PLTs from whole blood (i.e. 3 to 6 x 1011 PlTs). Advantages 
of apheresis platelet unit are recipient exposure to a single donor and the ability to 
match donor and recipient human leukocyte antigens (HLA) type, human platelet 
antigens (HPA) type and ABO blood type for certain recipients [2,7,8].
Figure 1. Donor Plateletpheresis
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Standard therapeutic dose of PLTs refers to 1 apheresis platelet unit or a pool 
of 4 to 6 whole blood–derived platelet concentrates, containing 3 to 4 × 1011 PlTs. 
Platelets are collected in bags that allow oxygen and carbon dioxide gas exchan-
ge, and stored at room temperature in special conditions (Platelet incubator with 
agitator - Figure 2.). The shelf life of stored platelets is five days (4-7) and they are 
frequently in short supply [2,7,9].
MODIFICATIONS OF PLATELET UNITS
Each unit of whole blood or unmodified platelet unit contains 2 to 5 x 109 con-
taminating leukocytes. Platelets can be leukoreduced to help prevent some tran-
sfusion reactions, such as febrile non-hemolytic reactions, HLA alloimmunization, 
transmission of different viruses (CMV, HTLV ½, EBV, HTLV, HSV, etc.), transfusion 
related acute lung injury (TRALI), and reduction of transfusion-associated immu-
nomodulation [7]. There are two major categories of leukoreduced platelets: presto-
rage and poststorage. The most effective current leukocyte reduction filters gene-
rally leave residual leukocyte counts below 1 x 106. 
Platelets can also be irradiated with a minimum dose of gamma irradiation of 25 
Gy in some clinical conditions, such as immunocompromised patients, bone marrow 
or stem cell transplants, intrauterine transfusions, neonatal exchange transfusion, 
Figure 2. Platelet incubator with agitator
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relative blood donors, and genetically homogeneous populations or HLA matched 
platelets. Irradiation inhibits the proliferation of viable T lymphocytes preventing 
serious side effect of transfusion therapy – transfusion associated graft versus host 
disease (ta-GvHD) [7].
Washed platelets are rarely prepared, only in the case of severe allergic or anap-
hylactic reaction to plasma proteins or in patients with existing anti-IgA antibodies 
due to IgA deficiency [10].
Volume-reduced platelets should be used in case of ABO-minor mismatched 
platelets or for transfusion of volume-sensitive patients [11].
Dosage and refractoriness to platelet transfusion
It is considered that the optimal dose of platelet transfusion for children is 
0.5×1011/10 kg, which is equivalent to one whole blood-derived platelet concentrate 
and 3.0×1011 in adults, which is one apheresis unit or a pool of 4-5 random donor 
platelets. Each platelet unit from whole blood should increase the platelet count by 
5-10,000 x 109/L in an average non-bleeding adult. This is roughly equivalent to a rise 
of 30,000/μL in platelet count in an average adult patient transfused with one unit of 
single donor apheresis platelets or an equivalent pool of random donor platelet. The 
10-minute and 1-hour post-transfusion platelet count increment can provide useful 
data on patient response to platelet transfusion. It is usually defined as platelet re-
covery. The formula most commonly used to calculate platelet count increment is: 
Absolute PLT increment/μL x body surface area (m2) / Number of transfused PLTs (1011)
The expected corrected platelet increment (CCI) after 10 minutes should be grea-
ter than 10,000/μL per m2 of body surface area. Platelet increments less than 5,000/μL 
indicate refractoriness. Platelet survival is evaluated by a platelet count obtained 24 
hours post-transfusion. It is considered that the platelet survival is satisfactory if the 
CCI is greater than 4,500/μL. Refractoriness to platelet transfusion may be caused 
by immune and non-immune mechanisms. Normal platelet recovery means nor-
mal increment at one hour following transfusion, with return to the baseline count 
within 24 hours (reduced platelet survival), and is typical for non-alloimmune cau-
ses. It is considered that a large number of refractory episodes occur because of non-
immune causes, such as sepsis, high fever, bleeding, splenomegaly, disseminated 
intravascular coagulation (DIC) and medications. In cases of non-immunological 
mechanism, it is necessary to treat the underlying cause of the disease, and increase 
the dosage of platelet units at least three times [7,12].
Refractoriness related to alloimmunization is caused by the antigens on the 
platelet surface, such as HLA Class I, HPA and ABO antigens. Reduced platelet re-
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covery (little or no increment in platelet count) within one hour of transfusion, de-
monstrated after at least two transfusions, is caused by alloimmunization. In cases 
of immune-mediated refractoriness, there are several strategies to consider when 
selecting platelets for such patients: provision of HLA-matched platelets or HLA 
"compatible" (antigen-negative) platelets, platelets selected by crossmatch tests (cro-
ssmatch-compatible platelets), and other medical treatments to reduce alloimmu-
nization. Some cases of refractoriness are a combination of both immune and non-
immune mechanisms [7,13,14].
There has been a long-lasting debate over whether the traditional threshold 
for prophylactic platelet transfusion of 20,000/μl is really necessary to prevent 
hemorrhagic complications. During the last 10 years several studies have pro-
ven the safety of more restrictive platelet transfusion strategies with a platelet 
transfusion trigger of 10,000/μl or even lower when patients are clinically stable 
without active bleeding. Such a strategy decreases the risk of infectious disea-
se transmission, early immunization, febrile and allergic transfusion reactions, 
and other discomforts for the patient, such as frequent hospital visits or a longer 
hospital stay, and reduces the costs of platelet transfusions by 20% - 30% com-
pared with traditional transfusion strategies [2,4,15-17]. There are some widely 
accepted recommendations for prophylactic platelet transfusions in various cli-
nical settings (Table 1.) [12].
Table1. Recommendations for prophylactic platelet transfusions 
Transfusion trigger
No. of platelets x 109 /L Recommendations for platelet transfusions 
<10 × 109 /L Prophylactically, to prevent spontaneous bleeding  (afebrile patients)
<20 × 109 /L Preparing for bone marrow aspiration/biopsy or elective central venous catheter placement, for low risk diagnostic procedures 
<30× 109 /L Prophylactically, to prevent spontaneous bleeding in fever, infection or sepsis, splenomegaly
<50 × 109 /L
Preparing for elective diagnostic lumbar puncture, endoscopic 
procedures or major elective surgery
<100 × 109 /L Preparing for intracranial (central nervous system) or intraocular bleeding; for neurosurgery or ocular surgery
There is no doubt that platelets should be transfused therapeutically, regardless 
of the PLTs number in actively bleeding patients with thrombocytopenia, massive 
blood loss, disseminated intravascular coagulation or cardiopulmonary bypass. 
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Platelet transfusions are not recommended in patients with immune throm-
bocytopenia, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome 
(TTP-HUS) and heparin-induced thrombocytopenia (HIT), only if patients have se-
rious bleeding, are at high risk of bleeding (e.g., after surgery), or require invasive 
procedures [12].
Platelet characteristics, such as platelet dose, platelet source (apheresis vs. poo-
led), platelet donor-recipient ABO compatibility, and duration of platelet storage, can 
affect post-transfusion platelet increments, but it is still unclear whether these factors 
impact platelet transfusion efficacy on clinical bleeding. Majority of clinical studies 
shows that they have no measurable impact on prevention of clinical bleeding [18]. 
Adverse effects of transfused platelets and their prevention
It is possible to decrease the incidence of alloimmunization to HLA Class I an-
tigens and subsequent alloimmune platelet refractoriness by utilizing leukocyte-re-
duced platelet units for transfusion (leukoreduction to below 1 x 106 cells). Patients 
who are alloimmunized and refractory to platelets are often difficult to manage, so 
it is helpful to try to prevent alloimmunization by transfusing leukoreduced blood 
products in patients likely to require long transfusion support [7,19].
Platelets express ABH antigens on their surface. It is recommended to give a 
transfusion of ABO- compatible or identical platelets whenever possible. In many 
transfusion centers, platelets are transfused without regard to ABO compatibility, 
due to short supply. Transfusions of ABO-incompatible platelets are associated with 
a reduced post-transfusion increment due to minor or major ABO mismatched tran-
sfusions, although the clinical significance is minimal and/or unclear. In ABO-mi-
nor mismatched platelets there are anti-A or anti-B antibodies, or both, which are 
incompatible with the recipient’s red blood cells, but there is a small risk of hemo-
lytic reaction that could be avoided by reducing the volume of incompatible plasma 
in platelet units. In ABO-major mismatched platelets there are ABH antigens on the 
surface of the platelets that can be destroyed by the recipient’s anti-A and/ or anti-
B antibodies, resulting in decreased post-transfusion platelet increments [20,21,22].
Platelet units also contain a small number of red blood cells that express Rh anti-
gens on their surface, which platelets do not express. The rate of anti-D alloimmuniza-
tion following the D+ platelet transfusion to a D- recipient is very low and depends on 
a variety of the patient’s clinical circumstances. However, transfusion centers avoid gi-
ving platelets from D+ donors to D- female patients because of the potential risk of RhD 
alloimmunization. In the case of transfusing D+ platelets to a D- recipient, Rh immune 
globulin (RhIg) should be administered to prevent D alloimmunization [20,23].
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Despite significant improvements in donor screening and laboratory testing, a 
small risk of viral, bacterial and protozoal contamination of platelets still exists. 
Some viruses, such as CMV (EBV, HTLV1/2), are transmitted by contaminated leu-
kocytes and could be avoided by leukoreduction. Bacterial contamination is more 
common in platelets than in red cell units due to storage at room temperature. The 
risk of bacterial infection could be reduced by appropriate skin sterilization tech-
niques during collection and by discarding the first 15 to 30 mL of blood collected, 
using assays to screen for bacterial contamination or using some of the methods of 
pathogen reduction or inactivation [7,9].
One of the rare but serious complications of platelet transfusion is transfusion-
associated graft-versus-host disease (ta-GvHD) that is mediated by viable donor 
lymphocytes. It occurs in two clinical settings: when the recipient is immunodeficient 
or immunosuppressed (e.g., from hematopoietic cell transplant and lymphoma), and 
when there is a specific type of partial HLA matching between the donor and the re-
cipient. The treatment of choice to prevent ta-GVHD is irradiation of platelet units [7]. 
Platelet units also contain plasma which can be implicated in adverse reactions, 
including severe allergic anaphylactic reaction to plasma proteins and transfusion-
related acute lung injury (TRAlI), a form of acute lung injury that causes respi-
ratory distress following transfusion. The risk of severe allergic and anaphylactic 
reaction could be reduced by using washed platelets. TRALI could be avoided by 
using platelets from male donors only, removing the plasma from the platelets and 
/or resuspending the platelets in platelet additive solutions [7].
Transfusion of platelets may be associated with circulatory overload: transfusi-
on-associated circulatory overload (TACO). The incidence of TACO is higher in pati-
ents predisposed to volume overload (e.g., in the elderly, in small children weighing 
up to 15 kg and in patients with congestive heart failure, renal failure, respiratory 
failure and positive fluid balance) [7].
Post-transfusion purpura (PTP) is a rare transfusion reaction that occurs in less 
than 2 percent of individuals who lack human platelet antigen 1a (HPA-1a), and 
have developed anti- HPA-1a antibody. Thrombocytopenia develops 5 to 10 days 
following transfusion [7].
CONCLUSIONS 
Many modern medical treatments and diagnostic procedures in thrombocyto-
penic patients depend on a constant supply of PLTs. The question still remains when 
platelets should be administered to minimize the risk of bleeding while maximi-
zing their benefit. There are still no substitutes for platelet transfusion that could 
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rapidly increase the platelet count in a bleeding patient. Given the high demand for 
their use, compromises must be made between providing the “ideal” platelet unit 
and the realities of blood bank supply. Each transfusion center must decide on its 
own priorities for providing safe and effective PLT transfusions.
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Sažetak
Transfuzijsko liječenje koncentratima trombocita
Od ranih 60-ih godina prošlog stoljeća, transfuzija koncentrata trombocita ima značajnu 
ulogu u liječenju hematoloških i onkoloških bolesnika s trombocitopenijom. Svake se godine u 
Europi transfundira više od 2,9 milijuna koncentrata trombocita i 57.000 u Hrvatskoj. Trombocit-
ne transfuzije već su dugi niz godina predmet brojnih rasprava i kontroverzi, posebice prednost 
profilaktičke u odnosu na terapijske transfuzije, okidač / ili prag za transfuziju trombocita, me-
tode prikupljanja trombocita te optimalnu dozu trombocita za transfuziju. Uzimajući u obzir da 
trombociti imaju kratak vijek trajanja u odnosu na druge krvne pripravke (5-7 dana), uz rastuće 
zahtjeve za njihovo korištenje, svaki transfuzijski centar mora odlučiti na koji će način osigurati 
dovoljan broj sigurnih i učinkovitih koncentrata trombocita. 
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